# A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

> **NCT03152552** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 125 (actual)

## Conditions studied

- Diabetes Mellitus and Heart Failure

## Interventions

- **DRUG:** LIK066
- **DRUG:** Placebo
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT03152552
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-25
- **Primary completion:** 2018-06-06
- **Final completion:** 2018-06-06
- **Target enrollment:** 125 (ACTUAL)
- **Why stopped:** This study terminated prematurely because of slow enrollment
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03152552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03152552, "A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03152552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*